cytochrome P450 family 2 subfamily F member 1Genealiases: C2F1 · CYP2F · CYPIIF1
Q-omics provides the consensus-scored CYP2F1 profile across patient tissues and cancer cell-line models. CYP2F1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, CYP2F1 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, CYP2F1 RNA expression shows 9,429 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, HNSC, and TGCT as cancer lineages where CYP2F1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP2F1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP2F1 survival associations across molecular data types. CYP2F1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP2F1 RNA expression–survival associations across cancer types. High CYP2F1 expression shows unfavorable associations in THCA, KIRC, UVM and ACC, but favorable associations in MESO and STAD. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for CYP2F1 RNA expression.
This table summarizes CYP2F1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP2F1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP2F1 shows lower tumor expression in HNSC, LUSC and LUAD and higher tumor expression in COAD, LIHC and READ. The HNSC box plot shows higher CYP2F1 RNA expression in normal versus tumor tissue (log2 FC = −1.646, t-test p < 0.001).
This table shows molecular features associated with CYP2F1 in patient tissues and cancer cell lines. In patient samples, CYP2F1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP2F1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
